Clinical evaluation of the oral probioticStreptococcus salivariusK12 in the prevention of recurrent pharyngitis and/or tonsillitis caused byStreptococcus pyogenesin adults
Authors:
- Francesco Di PierroFrancesco Di Pierro
- Teresa AdamiTATeresa Adami
- Giuliana RapacioliGRGiuliana Rapacioli
- Nadia GiardiniNGNadia Giardini
- Christian StreitbergerCSChristian Streitberger
- 20 November 2012
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 13 (3) , 339-343
Abstract
Streptococcus salivarius K12 has been shown to inhibit the growth of Streptococcus pyogenes due to bacteriocins release. Because of its ability to colonize the oral cavity, we have tested the strain K12 for its efficacy in preventing streptococcal pharyngitis and/or tonsillitis in adults. Forty adults with a diagnosis of recurrent oral streptococcal pharyngitis were enrolled in the study. Twenty of these subjects took for 90 days a tablet containing Streptococcus salivarius K12 (Bactoblis®). The other 20 subjects served as untreated controls. A 6-month follow-up was included to evaluate any persistent protective role. The 20 adults who completed the 90-day course of Bactoblis® showed a reduction in their episodes of streptococcal pharyngeal infection (about 80%). The 90 days treatment was also associated with an approximately 60% reduction in the incidence of reported pharyngitis in the 6-month period following use of the product. The product was well tolerated by the subjects with no treatment-related side effects or drop-outs reported. Prophylactic administration of Streptococcus salivarius K12 to adults having a history of recurrent oral streptococcal pathology reduced the number of episodes of streptococcal pharyngeal infections and/or tonsillitis.Keywords
This publication has 16 references indexed in Scilit:
- Screening for probiotic properties of strains isolated from feces of various human groupsJournal of Microbiology, 2012
- Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12European Journal of Clinical Microbiology & Infectious Diseases, 2008
- Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real‐time quantitative polymerase chain reactionOral Microbiology and Immunology, 2007
- Salivaricin A2 and the Novel Lantibiotic Salivaricin B Are Encoded at Adjacent Loci on a 190-Kilobase Transmissible Megaplasmid in the Oral Probiotic Strain Streptococcus salivarius K12Applied and Environmental Microbiology, 2007
- Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivariusAntonie van Leeuwenhoek, 2006
- Safety Assessment of the Oral Cavity Probiotic Streptococcus salivarius K12Applied and Environmental Microbiology, 2006
- A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parametersJournal of Applied Microbiology, 2006
- The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probioticsOral Diseases, 2005
- Bacterial replacement therapy: adapting ‘germ warfare’ to infection preventionTrends in Biotechnology, 2003
- Bacteriocins of gram-positive bacteria.Microbiological Reviews, 1995